James M. Frates

James M. Frates, listed as board member, has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Amylyx Pharmaceuticals, Inc. and Sage Therapeutics, Inc. We count 27 filings; the first trade dates from 16 June 2021 and the latest from 10 September 2026.

Both buying and selling appear: 2 purchases worth €175k, against 12 sales worth €1.7M. Taken together, the sales exceed the purchases by €1.6M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The rest of the record consists of 5 share grants and 5 option exercises. Since January 2026: no purchases and 5 sales on the market.

The latest filing, published on 14 September 2026, reports an open-market sale of €30k in Amylyx Pharmaceuticals, Inc. The most recent open-market purchase was published on 16 September 2024, 762 days ago. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.